Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 4/1998

01-08-1998 | SHORT COMMUNICATION

Superiority of hepatic arterial infusion in preventing catabolism of 5-FU compared with portal vein infusion revealed by an in vivo 19F NMR study

Authors: Kiyotaka Okuno, Norihiko Hirai, Yung Sun Lee, Dino Tarabar, Hideo Ueno, Masayuki Yasutomi

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/1998

Login to get access
Metadata
Title
Superiority of hepatic arterial infusion in preventing catabolism of 5-FU compared with portal vein infusion revealed by an in vivo 19F NMR study
Authors
Kiyotaka Okuno
Norihiko Hirai
Yung Sun Lee
Dino Tarabar
Hideo Ueno
Masayuki Yasutomi
Publication date
01-08-1998
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/1998
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800050827

Other articles of this Issue 4/1998

Cancer Chemotherapy and Pharmacology 4/1998 Go to the issue

ORIGINAL ARTICLE

Determination of flavopiridol (L86 8275; NSC 649890) in human plasma by reversed-phase liquid chromatography with electrochemical detection

ORIGINAL ARTICLE

A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice

ORIGINAL ARTICLE

Prevention of apomorphine- or cisplatin-induced emesis in the dog by a combination of methylnaltrexone and morphine

ORIGINAL ARTICLE

Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo

ORIGINAL ARTICLE

Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae

ORIGINAL ARTICLE

Quaternary ammonium analogs of ether lipids inhibit the activation of protein kinase C and the growth of human leukemia cell lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits